Biotech

All Articles

A better look at Intense Biotech's Brutal 15

.Within this week's incident of "The Best Pipe," we're diving in to Tough Biotech's annual Intense 1...

Lilly deals with phase 2 failing of tau-targeting med

.The confetti is still flying from Eli Lilly's gathering celebrating the approval of Alzheimer's dis...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our summary of considerable leadership hirings, firings and...

Lykos will inquire FDA to reassess its own decision observing rejection of MDMA therapy for trauma

.Adhering to an unsatisfactory presenting for Lykos Therapeutics' MDMA prospect for post-traumatic s...

AN 2 fifty percents roll call, stops stage 3 trial after records disappoint

.AN2 Rehabs is actually re-thinking its organization in action to lackluster midphase data, vowing t...

Merck pays for $700M for bispecific, snooping autoimmune opening and possibility to test Amgen in cancer cells

.Merck &amp Co. is actually spending $700 million beforehand to test Amgen in a blood stream cancer ...

Gilead pays out J&ampJ $320M to exit licensing deal for seladelpar

.With Gilead Sciences about to an FDA selection for its liver disease medicine seladelpar, the provi...

' All hands on deck' at Lilly as peers target being overweight market

.CEO David Ricks may find the companies setting up camping tents at basecamp behind Eli Lilly in an ...

Entero laying off staff, abandoning workplace and also stopping briefly R&ampD

.Cushion Liquidators has actually turned Entero Rehabs white as a sheet. The collector purchased Ent...

Exelixis drops ADC after choosing it is actually no match for Tivdak

.Exelixis is actually quiting on its own cells element (TF)- targeting antibody-drug conjugate after...